We used a difference in bias approach to evaluate the commutability of 4 frozen serum pools for 8 direct methods for measurement of HDL and LDL cholesterol (HDLC and LDLC).
Off-the-clot frozen serum pools are often used as secondary reference materials for external quality assessment (EQA) 8 and to establish calibration traceability. However, few published data are available to support the commutability of frozen serum pools with fresh individual patient sera for reference measurement procedures or routine direct methods for HDL cholesterol (HDLC) and LDL cholesterol (LDLC). Cobbaert et al. reported that 3 frozen off-the-clot serum pools showed good commutability in a paired laboratory "twin study" format with nonfrozen patient samples, and the frozen pools used as calibrators reduced interlaboratory CV to Ͻ4% (1 ) .
Commutability is defined as a property of a reference material, demonstrated by the closeness of agreement between the relation among the measurement results for a stated quantity in this material, obtained according to 2 given measurement procedures, and the relation obtained among the measurement results for other specified materials (2 ) . Consequently, an estimate of the bias observed between a routine method and a reference method is needed for a set of patient samples and for the reference materials being investigated. A reference material is considered commutable with patient samples for a given pair of measurement procedures when the difference in the biases is less than a critical value suitable for the intended use of the reference materials.
We examined the commutability of once-frozen off-the-clot serum pools for 8 direct methods for measuring HDLC and LDLC compared to the CDC betaquantification reference measurement procedure (CDCRMP). We evaluated commutability using an error model that identified systematic and random components, and we compared the conclusions from this approach to those that use a 95% prediction interval approach suggested by Clinical and Laboratory Standards Institute (CLSI) guidelines (3, 4 ) .
Materials and Methods

PATIENT SAMPLES
Patient sera used for this study were collected at Virginia Commonwealth University Medical Center and the NIH Clinical Center, with the approval of institutional review boards, as described for a previously reported study to compare results obtained for HDLC and LDLC by 7 direct methods and CDCRMP (5 ) . Sera from 138 diseased and 37 nondiseased patients were stored at 2-4°C and analyzed by all methods within 48 h of collection.
FROZEN SERUM POOLS
Frozen aliquots of 4 off-the-clot human serum pools were provided by the CDC. The frozen aliquots of the pools were prepared according to the CLSI C37 protocol (6 ), stored at Ϫ70°C, and shipped on dry ice. The 700-series pools were prepared in early 2007 and pool 804 in early 2008 for use in the CDC Lipid Standardization Program for laboratories. The values for HDLC and LDLC were assigned by CDCRMP by use of thawed once-frozen aliquots and were assumed to have negligible measurement uncertainty.
ANALYTICAL METHODS AND EXPERIMENTAL DESIGN
The direct methods for HDLC and LDLC were performed in 2008 and are described in the Supplemental Data, which accompanies the online version of this article at http://www.clinchem.org/content/vol61/issue8; they have also been described along with CDCRMP in a previous report (5 ) . A run consisted of the patient sera analyzed in triplicate (3 consecutive measurements) by each direct HDLC and LDLC method along with aliquots from the 4 frozen serum pools analyzed in duplicate at the beginning and the end of each run. Frozen serum pools were thawed at room temperature and mixed within 1 hour of the initiation of the run. The diseased samples were analyzed in 30 runs, and the nondiseased samples in 8 runs. Three runs were common, for a total of 35 runs. The number of patient samples in each run varied from 1 to 9.
For CDCRMP, each patient sample had 2 ultracentrifugation tubes, and each bottom fraction and heparinmanganese supernatant was measured in duplicate for cholesterol (in all, 4 cholesterol values for each component). For some samples, there were only 2 or 3 cholesterol values. The HDLC value for 1 diseased sample and the LDLC values for 3 diseased samples were missing and have been excluded from statistical analysis. One QC sample was measured in 4 (sometimes 2 or 3) vials with CDCRMP in each of the 35 runs.
STATISTICAL ANALYSES
Agreement between a routine measurement procedure and CDCRMP. We determined agreement by use of a difference plot between the mean values for each sample minus the corresponding CDCRMP values, B i , on the y axis against the CDCRMP value on the x axis. Such a difference plot can be described by 2 characteristics: a bias function and the scatter around this bias function. We used nontransformed data for analysis because the scatter width was approximately constant over the concentration interval. The statistical analysis and interpretation of a difference plot are simplified if the bias can be assumed to be constant over the measuring interval. This assumption was realistic (with 1 exception: Serotec LDLC, nondiseased) after exclusion of a few samples in the ends of the measuring intervals for some of the routine procedures. Obvious outliers were excluded: either 1 of the 3 replicates was aberrant and the remaining 2 values were used, or sample results with a large deviation from the CDCRMP value would inappropriately confound the assessment because of large sample-specific effects. Excluded values and samples are shown in online Supplemental Tables 1 and 2 .
After exclusions, we calculated the means and SDs of the differences B i for the patient samples, denoted B PS and s PS , respectively. The differences B i were not independent, as they were partly from the same runs. The number of samples also varied between runs. We have assumed, however, that B PS can be considered a reasonable estimate of the bias between the measurement procedures and that the standard uncertainty can be expressed by
where R PS is the number of runs (30 for diseased and 8 for nondiseased samples). A coverage factor equal to 2 was used to calculate the expanded uncertainty U(B PS ) with an approximate coverage of 95%. Because uncertainty on the basis of R PS probably gives an overestimation of the uncertainty, we also calculated the uncertainty with the alternate calculation using the number of samples instead of the number of runs in the denominator in Eq. (1), which probably gives an underestimation.
Commutability of reference materials (frozen pools).
A measure of commutability. For a reference material (RM), we have calculated the mean, B RM , and the SD, s RM , of the bias values from the 29 -35 runs with 4 replicates of the RM. The standard uncertainty for the B RM was expressed by
where R RM is the number of runs. A coverage factor equal to 2 was used to calculate the expanded uncertainty U(B RM ) with a coverage of approximately 95%. The difference D RM ϭ B RM Ϫ B PS was used as a measure of the commutability of the RM, with the standard uncertainty expressed by
This uncertainty value may be an overestimation if the sample-specific effects are dominant. A coverage factor of 2 was used to give an expanded uncertainty with a coverage of approximately 95%:
Separate values of D RM were calculated for diseased and nondiseased samples (i.e., with the same values of B RM but different values of B PS ).
Assessment of commutability. In the assessment of commutability, one compares the measure of commutability, D RM , with criteria determined from the intended use of the RM. In this case, noted as criterion 1, the value of ͉D RM ͉ should be compared with a maximum acceptable bias, bias max , determined from a clinical application requirement. The National Cholesterol Education Program (NCEP) has recommended a maximum bias of 5% for HDLC and 4% for LDLC measurements (7 ). These relative values were transformed to concentrations in milligrams per deciliter (bias A ) for each of the 4 frozen pools. One may also base the assessment of commutability on the SD of the differences between the measurement procedures, s PS , noted as criterion 2. A reasonable critical value is 2 ⅐ s PS because Ϯ2 ⅐ s PS corresponds to approximately 95% of the differences between the measurement procedures. A disadvantage with criterion 2 is that s PS contains contributions from both measurement procedures and depends on the number of runs and replicates.
For the interpretation of an uncertainty interval for commutability, we used the following approach. If the uncertainty interval is within the critical value, a conclusive decision can be made that the RM is commutable; conversely, a conclusive decision can be made that the RM is not commutable when the uncertainty interval is outside the critical value. The estimate s PS for criterion 2 is uncertain; however, for the decision about commutability we considered only the uncertainty of ͉D RM ͉ expressed by ͉D RM ͉ Ϯ U(D RM ). Ideally, an uncertainty interval should be small enough to make the risk of an inconclusive result acceptable or the impact of an erroneous decision within the uncertainty interval acceptable. The results of the commutability assessment in this study are presented as commutable, noncommutable, or inconclusive separately for the 2 criteria according to the following rules: (a) commutable when
Rule 1 is equivalent to testing the hypothesis that the true value of the closeness of agreement is larger than bias A or 2 ⅐ s PS at the 2.5% level of significance (1-sided test). Rejection of the hypothesis signifies commutability.
The commutability assessment was also performed with the alternative calculation of U(B PS ) that will decrease U(D RM ) and change some inconclusive results to commutable or noncommutable.
For comparison, in the online Supplemental Data, we have also assessed commutability according to the prediction interval approach described in the CLSI guidelines (3, 4 ) .
Estimation of error components contributing to the differences between measurement procedures.
The following error models were assumed to estimate the contributions of error components to the observed differences between the measurement procedures.
For CDCRMP,
and for the routine measurement procedure,
where x and y are the measured values of the measurand; is the expected value of the measurand for CDCRMP, considered the accepted reference value; ␦ is the common systematic error, bias, for a routine measurement procedure against CDCRMP under specified performance conditions and a specified population of patient samples; d is an error component specific to a patient sample (may be considered a random component in a population of patient samples); b is a random error component between runs; c is an error component between different positions within a run (possibly due to trends); and e is random error between consecutive measurements within a run.
All systematic errors were collected in the bias term; that is, the expected values of the random components are zero and the SDs are denoted e(x) , b(x) , e(y) , b(y) , and c(y) and were assumed to be at least approximately unrelated to the concentration. The values of ␦(m) and d depend on the specified population of samples. In more general models, the components ␦ and b are allowed to be functions of the concentration; see for instance Bachmann et al. (8 ) .
Components of variation within CDCRMP. The patient samples with 4 values have been used to estimate the SD between ultracentrifugation tube means ( tube-mean ), between tubes ( tube ), and between vials ( vial ). Between these SDs, we have the following relation:
The SDs between runs, s b(x) , and between vials, s vial , were estimated by ANOVA from the runs with 4 results for cholesterol for a QC sample. The measurements of the QC sample do not include the step with the ultracentrifugation tube. For that reason, it is uncertain whether the between-run variation is appropriate to apply to the patient samples. However, we have no other information.
The contribution from CDCRMP to the SD of the differences between procedures for patient samples is estimated by
This estimate is correct if all patient samples were measured in different runs. Because they were partially measured in the same runs, this estimate may be an overestimation.
Components of variation within the routine measurement procedures. From the triplicate measurements of patient samples, we calculated a pooled estimate of the SD within runs, s e . The duplicate measurements of the frozen pools in the beginning and end of each of 35 runs were analyzed with 2-way ANOVA. Only runs with all 4 measurements were used (Ն29). Runs were considered a random effect, and position (beginning and end), a fixed effect. The ANOVA gives estimates of the SDs of position effects, run effects (s b ), interactions (between runs and positions), and variation within duplicates (s e ). The position effect can be considered the systematic part of the pattern of variation within runs, and the interaction a random part of this pattern (varies between runs). The combined SD of position effects and interaction was used as an estimate of the total SD between positions, s c . With measurements from only 2 positions within the runs, there was limited information about the pattern of variation within runs. Pooled estimates of s b , s c , and s e were calculated. To estimate the SD of sample specific differences, we used the estimate s e from the patient samples.
Sample-specific differences between the measurement procedures. The SD of the sample-specific differences was estimated by
Separate estimates were calculated for diseased and nondiseased samples [i.e., separate values of s PS but the same values of the other components in Eq. (9)].
Results
Agreement between the routine measurement procedures and CDCRMP are shown in online Supplemental Tables  3 and 4 The SDs from the CDCRMP contributing to the differences between the routine procedures and CDCRMP, s x , were 1.10 mg/dL for HDLC and 1.54 mg/dL for LDLC. Error components contributing to the differences for the routine measurement procedures are presented in online Supplemental Tables 5 and 6 . As reported previously, the sample-specific differences, s d, were the dominating contribution to the disagreement between the routine procedures and the reference procedure (5 ).
Statistical measures for the commutability assessment are presented in online Supplemental Tables 7-14. Note that U(D RM ) is almost the same for each of the 4 frozen pools because the contribution from s B was the same, and this component dominated.
The criteria for acceptable commutability are presented in Table 1 (medical requirement based) and Table  2 (random error based). The conclusions regarding commutability of the frozen pools for each of the routine measurement procedures are shown in Tables 3-6. The medical requirement-based criteria were more stringent, with only pool 804 being commutable for most HDLC methods on the basis of nondiseased individuals but inconclusive for 3 methods on the basis of diseased individuals. Pool 804 was commutable for 1 LDLC method. No other pools were commutable for LDLC methods on the basis of medical requirements.
According to random error-based criteria, all of the frozen pools were generally commutable for all of the HDLC methods. Pool 804 was commutable for 6 of 8 routine methods for LDLC, with inconclusive results for the other 2 methods. Pool 715 had a mix of commutable, inconclusive, and noncommutable decisions for various LDLC methods, and the other 2 pools were noncommutable or inconclusive for all LDLC methods, suggesting that none of these 3 pools was suitable for assessing LDLC method performance.
The conclusions regarding commutability of the frozen pools on the basis of the 95% limits of agreement are shown in online Supplemental Tables 15 and 16 .
Discussion
Assessment of calibration standardization to a reference measurement procedure or harmonization of results among routine measurement procedures can be done only with commutable materials (9 ) . The 4 frozen pools evaluated were used as EQA samples by the CDC in its Lipid Standardization Program for laboratories, including total cholesterol, HDLC, and triglycerides; the program did not assess LDLC performance.
Commutability was evaluated in this study from the difference in bias for a RM and the average bias for a set of patient samples vs CDCRMP. The difference in bias is not influenced by calibration errors. Various types of random errors contributed to the uncertainty of the estimated differences in bias. This uncertainty was estimated and included in the comparison of the differences in bias (closeness of agreement) vs a commutability criterion.
Two types of commutability criteria were examined. Criterion 1 was based on a fixed proportional bias established by the NCEP as appropriate for medical interpretation of HDLC or LDLC results. Because the intended use of these frozen pools was to determine that a routine method was appropriately calibrated to satisfy these bias requirements, it was reasonable that the magnitude of any bias attributable to noncommutability should be less than this criterion. An advantage with this criterion is that it is determined from the intended use and not from the performance of the measurement procedures. Table 3 . Commutability decisions for HDLC according to criterion 1, medical requirement 5% bias. 
a When different, decisions using the alternative calculation of U(B PS ) are in parentheses. b C, commutable; NC, noncommutable; I, inconclusive.
Criterion 2, which was based on estimates of random error components derived from the data, was examined because it has similarities with other approaches for commutability assessment, such as the prediction interval approach or the relative residual approach recommended by CLSI guidelines (3, 4 ) . A key limitation of random error-based criteria is that they are more stringent for a more precise method and less stringent for a less precise method, allowing a RM to be classified as commutable for a method with poor performance characteristics but noncommutable for a method with good performance characteristics.
The commonly used prediction interval approach classifies a RM as commutable when its results are within a 95% prediction interval that represents the statistical distribution of patient sample results within which future observations will fall. An important difference between the assessment of commutability according to criterion 2 in the difference in bias approach and the prediction interval approach is that the uncertainty is neglected in the prediction interval approach, which is equivalent to testing the hypothesis of noncommutability on the 50% level of significance. An additional limitation of the prediction interval approach is its inability to use criteria on the basis of intended use, because the difference in bias between a RM and patient samples is not estimated. The online Supplemental Data contains additional discussion of approaches and criteria on the basis of random errors. We demonstrated different conclusions on the basis of each of the criteria. We propose that criteria on the basis of medical requirements are preferred.
Commutability was evaluated separately on the basis of results from diseased and nondiseased patients because the influence of differences in bias and sample-specific effects could not be excluded and could affect commutability decisions. For HDLC, the decisions based on medical criteria were altered in more than half of cases, with changes in both directions, but the overall conclusions for a pool were generally the same. Decisions regarding commutability for HDLC methods based on random error components were largely unaffected, probably because these criteria were less stringent and were different for each method, reflecting the magnitude of its random errors. Commutability decisions for LDLC methods were largely unaffected whether results from diseased or nondiseased individuals were used, probably because the magnitude of noncommutability bias was large relative to either criterion. These observations suggest that the choice of criteria for a commutability decision may be more important than influences of a disease condition for the final decision regarding commutability.
The results suggest that conclusions regarding traceability of routine methods to CDCRMP for HDLC should be based on concordance among results for a number of different frozen pools and that results for a single pool may not be a reliable indicator of bias. Similar limitations will apply when comparing results among a group of different routine methods for HDLC. The results suggest that frozen serum pools were likely to be noncommutable for LDLC methods and thus not reliable to assess the traceability of routine methods to the CDCRMP or to make comparisons of one routine LDLC method to another. For these reasons, the CDC Lipid Standardization Program for in vitro device manufacturers bases calibration traceability to CDCRMP for both HDLC and LDLC on results for nonfrozen individual patient samples.
The frozen pools were prepared according to the CLSI C37 protocol. Our results suggest that it is not appropriate to assume that pooled samples prepared by use of this protocol will always be commutable with patient samples and that validation of commutability remains important. Pool 804 was prepared the same year that the measurements were made and had better commutability characteristics on the basis of medical requirement criteria than the 700 series pools that were prepared the previous year. However, the experimental design was inadequate to determine if frozen storage had any systematic influence.
Strengths of this study were that 8 different direct methods for HDLC and LDLC were challenged with the same set of freshly collected nonfrozen serum samples from both healthy and diseased individuals and that 4 frozen off-the-clot serum pools were analyzed by all direct methods in each of 35 different runs. Commutability was examined by comparing the difference in bias, including its uncertainty, between the measurement procedures for patient samples and for frozen pools, with a fixed criterion on the basis of the intended use of the reference materials.
A weakness was the unbalanced allocation of serum samples to the different runs (1-9), which contributed to the uncertainty of the estimates of the error components.
The unbalanced design increased the complexity of making a correct calculation of the uncertainty of the difference in bias. Because the primary objective was to describe the difference in bias approach, we have used simple over-and underestimates of the uncertainty, which allowed suitable assessment of commutability since the conclusions were usually the same. Ideally, a balanced design should be used for commutability assessment.
